Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary
Bibliographic record
Abstract
Plain Language SummaryWhat is this summary about?The CodeBreaK 200 clinical study included patients with a type of lung cancer called non–small-cell lung cancer that has spread outside the lung (advanced) and had a particular change (mutation) in the KRAS gene. This mutation leads to the mutated protein called KRAS G12C and can lead to lung cancer. The CodeBreaK 200 clinical study looked at whether treatment with sotorasib works better and has fewer side effects than docetaxel. Sotorasib has accelerated approval or full approval for use in over 50 countries for patients with previouslytreated advanced KRAS G12C–mutated non–small-cell lung cancer.What did investigators find?There were 171 adults in the sotorasib group and 174 in the docetaxel group. The median time that patients in the sotorasib group whose disease was no worse or who did not die was 5.6 months. For patients in the docetaxel group, this was 4.5 months. After 1 year, 25% of patients in the sotorasib group had disease that was no worse or did not die. This happened in 100% of patients in the docetaxel group. In total, 48 out of 171 patients (28%) in the sotorasib group had a positive effect to treatment, and their tumors shrunk in size by at least 30% or disappeared. This happened in 23 out of 174 patients (13%) in the docetaxel group. Additionally, 141 out of 171 patients (82%) in the sotorasib group had tumors that either remained stable or shrunk in size. This happened in 105 out of 174 patients (60%) in the docetaxel group. Patients in both the sotorasib and docetaxel groups had a similar median survival (10.6 months in the sotorasib group compared with 11.3 months in the docetaxel group). Almost all patients treated with sotorasib or docetaxel had side effects. They were severe in 56 out of 169 patients (33%) receiving sotorasib and 61 out of 151 patients (40%) receiving docetaxel.What is the key takeaway?Sotorasib is an effective treatment for previously–treated patients with advanced KRAS G12C–mutated non–small-cell lung cancer.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".